Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder

This study, building on the lessons learned from the ADAPT Study; will further investigate the effectiveness and safety of a combination pharmacotherapy (XR-NTX; as Vivitrol® plus once-daily bupropion extended-release tablets) for methamphetamine use disorder. 

CTN Protocol ID: 
Completed ID: 

Principal Investigator(s)

Madhukar H. Trivedi, M.D.

Betty Jo Hay Distinguished Chair in Mental Health Professor, Node Principal Investigator
University of Texas Southwestern Medical Center
Department of Psychiatry

5323 Harry Hines Boulevard
Dallas, TX 75390
United States